{
  "id": 18512410,
  "title": "Sarepta quits enrolling for confirmatory Phase 3 trial of Elevidys",
  "url": "https://urgent.news/2026/11/06/sarepta-quits-enrolling-for-confirmatory-phase-3-trial-of-elevidys",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-06T14:10:47.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/sarepta-quits-enrolling-for-confirmatory-phase-3-trial-of-elevidys/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Sarepta Therapeutics won’t enroll more patients in the Phase 3 trial of its Duchenne muscular dystrophy gene therapy Elevidys, a test that was meant to act as confirmatory evidence for an approval in older boys. ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}